Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
October 2015
-
Stopping Alzheimer's disease before it starts
Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.
-
Media ReleaseKenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseasesNovartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and…
-
Featured NewsIndustry and academia collaborating to innovate for patients
We are partnering with the Friedrich Miescher Institute on more than 50 research projects to improve and extend people’s lives.
-
Media ReleaseNovartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 yearsLate-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had…
-
Media ReleaseLong-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven yearsNEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%…
-
Debunking the myths about multiple sclerosis
We surveyed 7,000 people in seven countries to find out what they know about multiple sclerosis (MS). Our survey identified several surprising misconceptions.
-
Media ReleaseAlcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgeryAcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval…
-
Media ReleaseFDA accepts Sandoz regulatory submission for a proposed biosimilar etanerceptEtanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
-
Novartis cancer researchers advance precision medicine
Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.
September 2015
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritisIn the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
-
Heart failure: coping with one of the world’s biggest killers
Patients are learning to live with a chronic disease that will affect one in 5 people over age 40.
-
Media ReleasePatients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
Pagination
- ‹ Previous page
- 1
- …
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- …
- 150
- › Next page